In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss how Bristol Myers Squibb (NYSE:BMY) can maximize the value of its LAG-3 inhibitor, relatlimab, now that the pharmaceutical company has shown it works with its PD-1 drug, Opdivo. On the flip side, the loser here could be Merck (NYSE:MRK), which has a PD-1 drug, Keytruda, but is currently lagging Bristol Myers Squibb in the LAG-3 arena.

Brian Orelli: I counted seven different programs in phase 2 for drugs that are targeting LAG-3: Incyte; Merck; Regeneron; Novartis, which is working with Immutep; and I think Immutep has one on their own; and there are some others.

Merck really stood out there since it has Keytruda, which competes with Opdivo. They're obviously combining [Bristol Myers Squibb's] LAG-3 with Opdivo. But Keytruda has really been taking market share, I think, from Opdivo in the PD-1 space. This really seems like the data that shows that Bristol's LAG-3 and Opdivo works well in melanoma, might give it a fighting chance to look at other indications before Merck has a chance to catch up.

Keith Speights: Yeah. I would agree. Merck and Bristol Myers Squibb are the top two players in PD-1 right now. But Keytruda, like you said, has emerged as the bigger winner in the head-to-head battle against Opdivo. But the next frontier for immunotherapies, I think, are in combination therapies, and we've already seen several combos win approval already, more likely on the way. But Bristol's lead in anti-LAG-3 could give it a pretty significant competitive advantage in the near future, and I think it's one that the company could really use. I think this could end up helping boost Opdivo's market position against Keytruda, if we see combo therapies come out.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.